Synbiotic as an Adjunct to Mechanical Treatment of Gingivitis

Smoking Clinical Trial

Official title:

The Effect of Synbiotic Tablet Usage on the Clinical and Biochemical Parameters in Smokers and Nonsmokers With Gingivitis: A Randomized Placebo-Controlled Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03455192
• Other study ID #: 2014/01
• Status: Completed
• Phase: N/A
• First received: February 16, 2018
• Last updated: February 27, 2018
• Start date: July 22, 2014
• Est. completion date: June 29, 2015

Study information

• Verified date: February 2018
• Source: Kirikkale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the efficacy of oral administration of synbiotic tablets on the clinical parameters and the levels of selected inflammatory mediators in gingival crevicular fluid (GCF) in smokers and non-smokers with gingivitis.

This study designed as a double-blind randomized placebo-controlled clinical trial.

Description:

Some patients like smokers have ongoing host response even after bacterial plaque removal achieved. Therefore efforts to develop effective treatment approaches remain an important objective in the treatment of gingivitis to prevent periodontitis especially in patients at high risk for developing periodontitis as smokers.

Smoking is a major risk factor for the incidence and the progression of periodontal diseases. The increased periodontal disease susceptibility in smokers is predominantly caused by changes in inflammatory and immune responses. Cigarette smoking also influences the amount and the composition of subgingival plaque. Smokers have higher numbers of pathogens in their resident biofilm and display an ongoing host response even after biofilm removal. Different approaches were explored to reduce the negative effects of smoking on the outcomes of periodontal therapy Synbiotic were defined as a mixture of probiotics and prebiotics that beneficially affects the host by improving the survival and implantation of live microbial dietary supplements in the gastrointestinal tract, by selectively stimulating the growth and/or by activating the metabolism of one or a limited number of health-promoting bacteria, and thus improving host welfare. Also in some cases, this may lead to a competitive advantage for the probiotics among with other bacteria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: June 29, 2015
• Est. primary completion date: June 29, 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Systemically healthy subjects

• Clinical diagnosis of gingivitis

Exclusion Criteria:

• Subjects who had used any systemic antibiotics in the previous 3 months,

• Subjects who had used a product containing probiotics in the previous month

• Systemic disease or condition that could interfere with the study results

• Ongoing drug therapy that could affect the signs of gingivitis

• Subjects who were received periodontal treatment in the last 6 months and

• Allergic to milk and milk products

Related Conditions & MeSH terms

• Gingivitis
• Gingivitis; Chronic
• Smoking

Intervention

Drug:
• Synbiotic Supplement

• Placebo Oral Tablet

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Kirikkale University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline Interleukin (IL)-6 level of GCF at 2 months	GCF samples were collected with paper strips and IL-6 levels of GCF were measured using commercial kits by using ELISA method	baseline, 1st and 2nd months
Primary	Change from Baseline IL-8 level of GCF at 2 months	GCF samples were collected with paper strips and IL-8 levels of GCF were measured using commercial kits by using ELISA method	baseline, 1st and 2nd months
Primary	Change from Baseline IL-10 level of GCF at 2 months	GCF samples were collected with paper strips and IL-10 levels of GCF were measured using commercial kits by using ELISA method	baseline, 1st and 2nd months
Secondary	Change from Baseline GCF volume at 2 months	Clinical parameter	baseline, 1st and 2nd months
Secondary	Change from Baseline Gingival Index at 2 months	Clinical parameter	baseline, 1st and 2nd months
Secondary	Change from Baseline Plaque Index at 2 months	Clinical parameter	baseline, 1st and 2nd months